Articles tagged with Huntingtons Disease
Researchers discovered that tauroursodeoxycholic acid (TUDCA) can cross the blood-brain barrier and reduce apoptosis in mice with the HD gene, improving neurological cell function. The bile acid's anti-apoptotic qualities may also have potential for treating other chronic neurodegenerative conditions.
Research by Dr. Lisa Ellerby at the Buck Institute suggests that calpain, a naturally occurring enzyme, plays a key role in Huntington's disease progression. The study uses post-mortem tissue and cell culture models to show that calpain activation is involved in brain damage.
The robotic microscope enables repeated analysis of cellular changes, allowing scientists to identify factors predicting cell fate and guide investigation into neurodegeneration. With the microscope, researchers can analyze 300,000 cells in just 15 minutes, reducing laborious tasks and eliminating bias.
Researchers have successfully mapped the genetic regions responsible for Hirschsprung disease, a rare inherited disorder affecting the intestines. The study reveals that three crucial regions on chromosomes 3, 10, and 19 contribute to the disease's complex inheritance pattern.
Researchers found that cystamine treatment alleviated tremors and prolonged lifespan in mice with neurological disorder mimicking Huntington's. The study suggests a similar treatment strategy may be effective in humans, highlighting the potential for neuroprotective proteins to counteract the disease.
A recent Mayo Clinic study suggests that the full-length mutant protein is responsible for toxicity in Huntington's disease, challenging traditional theories of clip-and-release. This new understanding may lead to more effective therapies by targeting the aberrant interactions of the mutant protein.
A new study found that the secretory path's activity is closely tied to the nucleus' structure and functions, with disruptions impacting gene expression and cellular growth. This research may hold key to developing molecular therapies for these genetic diseases.
A study of 347 patients found that CoQ10 slowed the decline of patients with Huntington's disease by an average of 15 percent, improving cognitive skills and daily responsibilities. However, the results are inconclusive due to limited patient numbers, and more research is needed before CoQ10 can be recommended as a treatment.
A large-scale clinical trial tested two investigational drugs, remacemide and Coenzyme Q10, to slow the progression of Huntington's disease. While Coenzyme Q10 seemed to improve the condition after one year, the overall results are inconclusive as to its effectiveness in slowing down the disease.
A University of Iowa study found that individuals who test negative for Huntington disease often experience doubts and guilt rather than relief. They struggle to redefine their goals and purpose in life after learning they don't carry the gene mutation.
Scientists have discovered that mutant protein fragments selectively accumulate in the nuclei and axon terminals of neurons in the brain affected by Huntington's disease. This accumulation is thought to inhibit neurotransmitter release, causing the death of specific neurons.
Researchers used a mouse model to identify changes occurring in nerve cells before the onset of Huntington's disease. They identified several signaling molecules that could be targeted for future therapies.
Researchers have created a transgenic mouse model of Huntington's disease, exhibiting progressive behavioral and motor dysfunction. The mice developed similar neuropathological changes to those seen in human Huntington's disease, with symptoms worsening as the abnormal gene load increased.
Researchers at Emory University report that a growth factor stimulation increases new neurons in the brain's striatum and cortex, raising hope for treating neurodegenerative diseases. The study confirms previous findings on adult mammalian forebrain's capacity to produce new neurons.
A $6.5-million study, the largest of its kind, aims to prevent deterioration in patients with Huntington's disease. The CARE-HD trial tests two treatments: experimental drug Remacemide and nutritional supplement CoQ10 to slow disease progression.
A transgenic mouse model of Huntington's disease has been developed, exhibiting symptoms resembling chorea and epileptic seizures. The R-6 strain is the first known mouse model to display these characteristics, allowing researchers to study the disease's progression.